Chronic administration of ketamine for analgesia

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 21, Issue 1, 2007, Pages 7-14

  Ben Ari, Alon ^a   Lewis, Michael C ^a,b   Davidson, Elyad ^a,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; Efficacy; Ketamine; Neuroaxial; Neuropathic; Pain; Phantom; Postherpetic neuralgia; Safety; Topical

Indexed keywords

ANTIDEPRESSANT AGENT; BENZETHONIUM CHLORIDE; CAPSAICIN; KETAMINE; LIDOCAINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE; PHENCYCLIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; ANALGESIA; CANCER PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEX REGIONAL PAIN SYNDROME; DRUG FORMULATION; DRUG POTENCY; DRUG PROTEIN BINDING; EPIDURAL ANESTHESIA; GLIOSIS; HUMAN; HYPERALGESIA; LIPID SOLUBILITY; LOADING DRUG DOSE; MONOTHERAPY; MOUSE STRAIN; NEUROPATHIC PAIN; PHANTOM; POSTHERPETIC NEURALGIA; QUESTIONNAIRE; RADICULOPATHY; RAT STRAIN; REVIEW; SCIENTIFIC LITERATURE; SPINAL CORD; UNSPECIFIED SIDE EFFECT;

ANALGESICS; ANIMALS; CHRONIC DISEASE; HUMANS; KETAMINE; NEOPLASMS; PAIN, INTRACTABLE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHANTOM LIMB; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34247253853     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1300/J354v21n01_04     Document Type: Review

References (62)

1. Domino E. Chidiff P, Corssen G. Pharmacologic Effects of CI581 a new dissociative anesthetic in human. Clin Pharmacol Therap. 1965; 6:279-91.
2. Wall PD, Melzack R: Text book of pain, 5th ed. Edinburgh, Churchill Livingstone, 2005.
3. Kohrs R, Durieux ME. Ketamine: Teaching an old drug new tricks. Anesth Analg. 1998; 87:1186-93.
4. Hurstveit O, Maurset A, Øye I. Interaction of the Chiral forms of Ketamine with opioid, phencyclidine, and muscarinic receptors. Pharmacol Toxicol. 1995;77:335-59.
5. White PF, Schuttler J, Shafer A, et al. Comparative pharmacology of the ketamine isomers: studies in volunteers. Br J Anaesth. 1985;57:197-203.
6. Martindale SJ, Dix P, Stoddart PA. Double-blind randomized controlled trial of caudal versus intravenous S(+)-ketamine for supplementation of caudal analgesia in children Br J Anaesth. 2004;92: 344-7.
7. Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration J Pain Palliative Care Pharmacotherap. 2002;3:27-35.
8. Vranken JH, Dijkgraaf MG, Kruis MR, van Dasselaar NT, van der Vegt MH. Iontophoretic administration of S (+)-ketamine in patients with intractable central pain: a placebo-controlled trial. Pain. 2005;118:224-31.
9. Smith DJ, Bouchal RL, DeSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, Crisp T. Properties of the interaction between ketamine and opiate binding sites in vivo and vitro. Neuropharmacol. 1987;26:1253-60.
10. Smith DJ, Perrotti JM, Mansell AL, Monroe PJ. Ketamine analgesia is not related to an opiate action in the periaquaductal gray region of the rat brain. Pain. 1985;21:253-5.
11. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991 44:293-9.
12. Burton AW, Lee DH, Saab C, Chung JM. Preemptive intrathecal ketamine injection produces a longlasting decrease in neuropathic pain behaviours in a rat model. Reg Anesth Pain Med. 1999; 24:208-13.
13. Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage. 1999;18:61-6.
14. Kvarnstro A, Karlsten MR, Quiding H, Gordh BT. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand. 2004;48:498-506.
15. Vick PG, Lamar TJ. Treatment of central poststroke pain with oral ketamine. Pain. 2001;92:311-3.
16. Kvarnstro A, Karlsten MR, Quiding H, Gordh BT, Emanuelsson BM. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand. 2003;47:868-77.
17. Carlton SM. Peripheral excitatory amino acids. Curr Opin Pharmacol 2001; 1:52-6.
18. Davidson EM, Carlton SM. Intraplantar injection of dextromethorphan, ketamine or memantine attenuates formalin-induced behaviors. Brain Res. 1998;785: 136-42.
19. Warncke T, Jorum E, Stubhaug A. Local treatment with N-methyl-D-aspartate receptor antagonist ketamine, inhibits development of secondary hyperalgesia in man by a peripheral action. Neurosci Lett. 1997;227:420-1.
20. Pedersen JL, Galle TS, Kehlet H. Peripheral analgesic effects of ketamine in acute inflammatory pain. Anesthesiology. 1998;89:58-66.
21. Gammitoni A, Gallagher RM, Wels-Bosna M. Topical ketamine gel: possible role in treating neuropathic pain. Pain Med. 2000;1:97-100.
22. Lockhart E. Topical combination of amitriptyline and ketamine for post herpetic neuralgia. J Pain. 2004;5(Suppl):82.
23. Donahue JE, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-9.
24. Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind crossover trial. Pain. 1992;48:29-36.
25. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs. 2000;60:1029-82.
26. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44.
27. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324-32.
28. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H . Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 1994;58:347-54.
29. Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 1995;61:221-8.
30. Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain. 1994;10:240-2.
31. Quan D, Wellish M, Gilden DH. Topical ketamine treatment of postherpetic neuralgia. Neurology. 2003:60;1391-2.
32. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004;5:263-75.
33. Jensen TS, Krebs B, Nielsen J, Rasmussen P. Immediate and long-term phantom limb pain in amputees: incidence, clinical characteristics and relationship to pre-amputation pain. Pain. 1985;21:267-78.
34. Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom limb pain: A central neuropathic pain. Pain. 1996;67:69-77.
35. Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of postamputation stump pain. Acta Anaesthesiol Scan Pain. 1993;54:227-30.
36. Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anesthesiol. Scand. 1997;91(3); 427-9.
37. Hayes C, Armstrong-Brown A, Burstal R. Perioperative intravenous ketamine infusion for the prevention of persistent post-amputation pain: a randomized, controlled trial. Anaesthesia Intensive Care 2004; 32;30-8.
38. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003;26:867-75.
39. Kozek SA, Sator-Katzenschlager S, Kress HG. Intrathecal S (+)-ketamine in refractory neuropathic cancer pain. Pain. 2006;121:283-4.
40. Carr DB, Goudas LC, Denman WT et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108:17-27.
41. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage. 2005;30:485-91.
42. Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. "Burst" ketamine for refractory cancer pain: An open-label audit of 39 patients. J Pain Symptom Manage 2001;22:834-42.
43. Yang et al. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anesth 1996;43:379-83.
44. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage. 1995;10:564-8.
45. Vranken JH, Van der Vegt MH, Kal KE, Kruis MR. Treatment of neuropathic cancer pain with continuous intrathecal administration of S +-ketamine. Acta Anaesthesiol. Scand. 2004;48:249-52.
46. Benrath J, Scharbert G. Gustorff B, Adams HA, Kress HG. Long-term intrathecal S (+)-ketamine in a patient with cancer-related neuropathic pain. Br J Anaesth. 2005;95:247-9.
47. Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH. Neuropathological findings after continuous intrathecal administration of S (+)-ketamine for the management of neuropathic cancer pain. Pain. 2005;117:231-5.
48. Byer DE, Gould AB Jr. Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology. 1981;54:255-6.
49. Khan MS, Bhatti AH. Ketamine tolerance. Postgrad Med J. 1988; 6:833-4.
50. Stevens RW, Hain WR. Tolerance to rectal ketamine in paediatric anaesthesia. Anaesthesia.1981;36:1089-93.
51. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002;30:382-4.
52. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003.44:31-4.
53. Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics 1999;40:356-9.
54. Hurt PH, Ritchie EC. A case of ketamine dependence (letter). Is J Psychiatry. 1994;151:779.
55. Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation' and analgesia of children in the pediatric intensive care unit. Crit Care Med. 2000;28:2122-32.
56. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage. 1999;17:384-6.
57. Dillon P, Copeland J, Jensen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69:23-8.
58. Dillon P, Copeland J, Jansen K, Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health-Syst Pharm. 2002;59:1067-76.
59. FDA Drug Bull 1979;5(9):24.
60. Gill JR, Stajic M. Ketamine in non-hospital and hospital deaths in New York City. Journal of Forensic Science. 2000;45:655-8.
61. Taffe MA, Davis SA, Gutierrez T, Gold LH. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend. 2002;68:175-87.
62. Morgan CJ, Riccelli M, Maitland CH, Curran HV. .Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend. 2004;75:301-8.